Bleakley Financial Group LLC Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Bleakley Financial Group LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 40.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,881 shares of the medical research company’s stock after purchasing an additional 2,281 shares during the quarter. Bleakley Financial Group LLC’s holdings in IQVIA were worth $1,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. E. Ohman J or Asset Management AB grew its position in IQVIA by 12.1% in the fourth quarter. E. Ohman J or Asset Management AB now owns 8,361 shares of the medical research company’s stock worth $1,643,000 after acquiring an additional 900 shares in the last quarter. GDS Wealth Management boosted its holdings in shares of IQVIA by 8.4% in the 4th quarter. GDS Wealth Management now owns 59,529 shares of the medical research company’s stock worth $11,698,000 after purchasing an additional 4,636 shares in the last quarter. Oregon Pacific Wealth Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at about $470,000. Magnolia Capital Advisors LLC raised its holdings in shares of IQVIA by 2.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock valued at $516,000 after buying an additional 74 shares in the last quarter. Finally, Western Pacific Wealth Management LP boosted its stake in IQVIA by 44.4% in the fourth quarter. Western Pacific Wealth Management LP now owns 845 shares of the medical research company’s stock worth $166,000 after buying an additional 260 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQV stock opened at $208.13 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $37.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. The business’s fifty day moving average is $200.53 and its 200 day moving average is $219.80. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. Research analysts expect that IQVIA Holdings Inc. will post 10.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IQV. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Redburn Atlantic assumed coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Finally, Truist Financial lowered their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.